CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in ...

- Continued active treatment in the OVERTURE II OLE study demonstrated durability and preservation of brain structure and volume via MRI measurements over 18 months - Spectris™ treatment was well ...

Results from OVERTURE showed Spectris preserved white matter and myelin integrity across multiple brain regions, indicating structural neuroprotection. The OVERTURE study demonstrated that Spectris ...

CAMBRIDGE, Mass., March 05, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...

New data from Cognito Therapeutics has indicated that its Spectris device increases cerebrospinal fluid (CSF) HDL-like lipid transport particles, suggesting the neuromodulation therapy prompts a ...

Cognito Therapeutics to Present New Data Highlighting Effects of Spectris™ on Lipid Transport Biomarkers in Alzheimer’s Disease at AAIC 2026 Company to present data demonstrating increases in CSF ...

Unbiased cerebrospinal fluid proteomics identify coordinated increases in HDL-like lipid transport proteins and myelination pathways following investigational Spectris™ sensory stimulation Cognito ...

New findings highlight correlations between EEG and clinical outcome measures in Alzheimer’s disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--#ADPD2026--Cognito Therapeutics, a late clinical-stage ...